Trial reportAnnals of clinical and translational neurology2026
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants.
Trial report in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02576717 (A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveReturn of disease activity is expected when patients discontinue disease-modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher-than-expected disease activity (rebound) after discontinuation. This exploratory analysis assessed disease activity and risk of rebound after ozanimod discontinuation.
methodsDAYBREAK (NCT02576717; October 2015-April 2023) was a single-arm, open-label extension trial of ozanimod 0.92 mg/d in participants with relapsing MS who completed phase 1-3 ozanimod trials. Two protocol amendments increased the required safety follow-up from an initial 28 days to 75 and then 90 days. Confirmed post-treatment relapses were characterized.
resultsOf 2494 participants, 1679 participants had ≥ 1 day of follow-up and did not initiate commercial ozanimod in ≤ 14 days of exiting the trial; 30.6% had ≤ 60 days of post-treatment follow-up. Fifty-five participants (3.3%) had known post-treatment relapse. Fifty-four were not taking an MS DMT when they relapsed; one relapsed soon after starting fingolimod. Relapses were associated with Expanded Disability Status Scale (EDSS) score increases of 0-3 points (median 1 point); the participant with the 3-point increase had a moderate relapse and complete recovery in 23 days. Forty-two participants (76.4%) fully recovered, 11 (20.0%) partially recovered, and 2 (3.6%) did not recover. Only one (1.8%) relapse was considered severe by the investigator: EDSS increased from 7.5 to 8.0, and the participant partially recovered within 36 days.
interpretationMost participants did not relapse within 90 days following ozanimod discontinuation. Post-treatment relapse cases suggestive of a rebound effect were not observed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.